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Abstract: The evaluation of biological responses to polymeric scaffolds are important, given
that the ideal scaffold should be biocompatible, biodegradable, promote cell adhesion and
aid cell proliferation. The primary goal of this research was to measure the biological
responses of cells against various polymeric and collagen electrospun scaffolds (polycaprolactone
(PCL) and polylactic acid (PLA) polymers: PCL–drug, PCL–collagen–drug, PLA–drug and
PLA–collagen–drug); cell proliferation was measured with a cell adhesion assay and cell viability
using 5-bromo-2′-deoxyuridine (BrdU) and resazurin assays. The results demonstrated that there is a
distinct lack of growth of cells against any irgasan (IRG) loaded scaffolds and far greater adhesion
of cells against levofloxacin (LEVO) loaded scaffolds. Fourteen-day studies revealed a significant
increase in cell growth after a 7-day period. The addition of collagen in the formulations did not
promote greater cell adhesion. Cell viability studies revealed the levels of IRG used in scaffolds
were toxic to cells, with the concentration used 475 times higher than the EC50 value for IRG.
It was concluded that the negatively charged carboxylic acid group found in LEVO is attracting
positively charged fibronectin, which in turn is attracting the cell to adhere to the adsorbed proteins
on the surface of the scaffold. Overall, the biological studies examined in this paper are valuable
as preliminary data for potential further studies into more complex aspects of cell behaviour with
polymeric scaffolds.
Keywords: electrospinning; aligned fibrous scaffolds; cell biology; nanofibers
1. Introduction
The challenge facing surgeons using mesh scaffolds in tissue engineering applications are two-fold:
first, controlling the way the fibres being used physically transform and symbiotically interact with
the host body’s physiological function; and more importantly, minimising or negating complications
such as chronic infections, development of adhesions, chronic pain and mesh rupture. Drug-loaded
oriented scaffolds can be created using a number of processes, including electrospinning, a fibre
production method utilising electric force against polymeric solutions. However, despite the various
characterisation methods one can perform on these scaffolds, there is a requirement to understand and
measure fundamental biological responses. In particular, ideal scaffolds for tissue engineering should
be biocompatible, biodegradable, promote cell adhesion and proliferation and have no detrimental
effect on cell bioenergetics [1]. Materials such as polycaprolactone (PCL), polylactic acid (PLA) and
collagen have achieved biocompatible and biodegradable requirements [2]. However, measuring the
effect of any biopolymer on cell adhesion, cell proliferation and cell metabolic activity remains the
crucial aspect in determining biocompatibility. Another important biological requirement is assisting
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the suppression of potential bacterial infections at the site of surgical/scaffold implant. Controlling any
bacterial infection is a vital pre-requisite to any potential cell growth, given that the cell/tissue viability
in the presence of bacteria such as Staphylococcus aureus or Escherichia (E.) coli will be profoundly
compromised [3].
Staphylococcus (S.) aureus is a gram-positive bacterium that is commonly found in nasal passages,
skin and mucous membranes [4]. This is a major cause of infection of wounds (in particular nosocomial
bloodstream infections), especially in surgical procedures that involve medical device implants [5].
Currently, within hernia mesh repair, 68% of infection complications are attributed to the S. aureus
infections; any infections related to hernia repair will increase the recurrence rates of hernia, meaning
that inhibiting the growth of this bacterium will give the patient a better chance of recovery [6]. E. coli
is another bacterium that can have detrimental effects on the recovery of wounds—it is the most
common pathogen found in the hernia sac [7]. This bacterium tends to develop in fluid collections at
the site of mesh implant. If this is found at the site of implant, typically drainage of the bacterial fluid
and a course of antibiotics are administered (e.g., ceftriaxone and ampicillin) [8]. However, if both
S. aureus and E. coli can be controlled without further administration of antibiotics (which would in
turn reduce the possibility of antibiotic resistance), invasive drainage procedures or overall removal
of hernia mesh can be avoided – this increases the chance of patient recovery and a better chance of
tissue re-growth at a cellular level.
The proliferation of cells related to the healing of wounds is also important within a hernia
repair context. Typically, wound healing can be divided into four main steps: (1) haemostasis (0–7 h);
(2) inflammation (1–3 days); (3) proliferation (4–21 days); and (4) remodelling (21 days–1 year) [9].
The proliferation period is arguably one of the most important phases given that there is a focus
on restoring the tissue network; this can be easily disrupted through any potential infection. Another
important aspect of the proliferation stage is the formation of the extracellular matrix (ECM); proper
formation of the ECM will help with cell adhesion and regulate growth, movement and differentiation
of the cells growing within it. If electrospun scaffolds can mimic the ECM successfully, they may help
promote cell adhesion, growth, movement and differentiation [10].
Tissue engineered scaffolds have been used in a number of different clinical applications;
in particular, there are a range of applications that are currently being applied within the field of
dentistry [11]. Other clinical applications include cardiac tissue engineering (e.g., culturing cells
onto a biomaterial scaffold in-vitro and then implanting tissue onto cardiac surface [12]), nerve
regeneration for the treatment of stroke (e.g., nanomaterials have been used as a biomimetic in order to
induce neuronal growth and guide brain regeneration [13]) and the treatment of pulmonary diseases
(e.g., porous scaffolds that mimic alveolar units to allow for greater cell adhesion for lung tissue
regeneration [14]).
Studies involving the testing of cellular response against electrospun scaffolds have been have
been well reported in the literature: testing cell migration of breast cancer cells (MDA-MB-231)
against PCL scaffolds [15], rat periodontal ligament cells against poly(lactic-co-glycolic acid; PLGA)
scaffolds [16], human umbilical vein endothelial cell (HUVEC) against PCL–collagen scaffolds [17] and
human mesenchymal stems cells against PLA scaffolds [18]. In particular, some of these studies
showed evidence that cells typically form confluent monolayers on electrospun scaffolds; fibre
orientation affects cell alignment and cells prefer to grow on aligned fibres (e.g., cells showed greater
attachment to specifically aligned fibres in comparison to randomly oriented scaffolds) [19]. Though the
studies mentioned successfully demonstrated a range of cellular behaviours on electrospun scaffolds,
there is a dearth of research that focuses on the cellular response in the presence of drug-loaded
electrospun scaffolds.
Therefore, the primary goal of this study was to measure the biological responses of cells
against a number of scaffolds (PCL–drug, PCL–collagen–drug, PLA–drug and PLA–collagen–drug
variations); cell proliferation was measured with a cell adhesion assay, with subsequent
fluorescent and scanning electron microscopy (SEM) imaging and cell viability using resazurin
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and 5-bromo-2′-deoxyuridine (BrdU) assays. The cell viability assays were chosen specifically
(in particular the resazurin assay) for quick determination of cell viability. Other assays, such as
the MTT (3-(4,5-Dimethylthiazol-2-Yl)-2,5-Diphenyltetrazolium Bromide) assay, have been used [20];
however, the use of DMSO in this assay has the potential to begin to degrade the polymeric samples.
The results in this paper amplify the importance of a number of factors described in previous
reports [21,22], such as the importance of hydrophobicity/hydrophilicity of the scaffolds, drug release
rates, drug concentrations and fibre morphology.
2. Materials and Methods
2.1. Materials
PCL with a mean molecular weight of 80 kD, PLA with a mixed molecular weight,
irgasan (IRG, variation of Triclosan, >97%), levofloxacin (LEVO, >98%), solvents used for the
electrospinning consisting of chloroform (anhydrous, containing amylenes as stabilizers, >99%) and
N,N-dimethylformamide (DMF, anhydrous 99.8%) and collagen from calf skin (Bornstein and Traub
Type I) were all obtained from Sigma Aldrich (Poole, UK).
2.2. Electrospinning of Polymeric Scaffolds
The polymer test specimens were fabricated for each polymeric solution using a custom in-house
electrospinning apparatus, which consisted of a syringe pump (Harvard Apparatus PHD 2000 infusion,
Cambridge, UK) and two 30 kV high-voltage power supplies (Alpha III series, Brandenburg, UK).
The polymer solution was loaded into a glass syringe and fed through tubing with a metal needle tip
attached at the end. The needle was clamped into place to allow a high-voltage supply to run through
it, which allowed an electric field to be created between the needle and the target plate. The syringe
was clamped to a pump, which determined the specific injection flow rate of the polymeric solutions.
For each of the three solutions (e.g., unloaded, irgasan-loaded and levofloxacin-loaded), 3 varying
flow rates of 0.5, 1 and 1.5 mL·h−1 were applied across varying voltages of 2 kV–5 kV (needle) and
10 kV–18 kV (target plate) [21]. The variation in flow rate and applied voltages were to correct any
problems that occurred during fabrication, i.e., ‘spitting’ of the solution at the target plate, or any
potential beading (which was examined through SEM). The fabrication of this solution was electrospun
onto a target that was covered with aluminium foil, in order for the final material to be removed and
used for further characterisation. The final yield of electrospun polymers resulted in thin, flexible
sheets of material.
2.3. Microscopic Characterisation
The morphology and diameter of individual fibres spun from the PCL solution were determined
from scanning electron micrographs of each sample (TM-1000®, Hitachi, Ltd., Maidenhead, UK).
The samples were mounted on an aluminium plate with conductive tape. Images of fibres were taken
at various locations of each electrospun PCL scaffold in order to determine the overall uniformity of
fibres. Prior to imaging, the samples were sputter coated with gold for 30 s using a Leica EM ACE200®
vacuum coater, the process being repeated four times in order to increase the conductivity of the
samples. The samples were imaged in secondary electron mode at 5 kV.
2.4. Cell Adhesion and Proliferation
Rat aortic smooth muscle cells (RAOSMCs) were explanted from 12-week-old male
Sprague-Dawley rats. Aortic rings (5 mm) were placed in T25 flasks in media (10% fetal calf serum
(FCS); 50:50 Waymouth and F12; 1% penicillin/streptomycin). The medium was changed every 72 h
and growth was monitored using a light microscope until cells reached ~70% confluency (Passage 0).
Cells were then split into T75 flasks and allowed to grow to ~70% confluency (Passage 1). Cells were
then again split into six well plates, 24 well plates or 96 well plates for further analysis.
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Cell adhesion was monitored in 24-well plate dishes with cells seeded directly onto electrospun
scaffolds. Square electrospun scaffolds (1 cm × 1 cm) were sterilized using short-wave UV irradiation.
Three samples were used per group, plus 1 control (scaffold containing no drug or collagen) and
repeated on 2 more well plates. Scaffolds were then pre-wet with media and placed in tissue culture
plates. Cells (at the previously mentioned density) in a volume of 100 µL were seeded directly onto
each scaffold, incubated at 37 ◦C for 4 h in order for the cells to adhere to the surface. Each well was
then filled with 2 mL of growth medium.
Initially, the RAOSMCs were left for 3 days to judge the adhesion of cells on the scaffold surface,
and then RAOSMCs were tested for proliferation within 14 days of seeding. In this case, media was
replaced every 3 days, and scaffolds were removed at 3, 7 and 14 days in order to image cells on
the scaffold (using fluorescent microscopy). Adhesion and proliferation were determined through
the staining of dead cells using propidium iodide (PI), a red-fluorescent nuclear and chromosome
counterstain. This process involved lifting the scaffolds from the wells, washing them with PBS buffer
and fixing the cells using 5% paraformaldehyde. Samples were then placed in 1 mL of PBS buffer, and
10 µL of PI solution was added and left in dark storage for approximately 30 min. Samples were then
placed on a coverslip, then subsequently imaged on a Nikon Eclipse E600 Epiflurorescent Upright
Microscope (Nikon, New York, NY, USA), at wavelengths of 495 nm (FITC) and 532 nm (TRITC). Cells
were then counted using ImageJ software (Version 1.52, National Institutes of Health, Wisconsin, WI,
USA). Images were converted to greyscale; the image threshold was altered to display a black and
white image highlighting the cell nuclei. A watershed function was then applied to separate cells
that were grouped close together, and a particle analyser was run at a measurement of minimum
100–120 pixels and a circularity range of 0.00–1.00.
2.5. Cell Viability Assay
In order to measure the cell viability against the levels of drug used in the electrospun scaffolds,
a resazurin assay was performed. Cells (RAOSMCs) were grown in 1% FCS, 10% FCS, 1% addition
of IRG or addition of 0.5% addition of LEVO, at a density of 3 × 104 cells/cm2 (in 24-well plates)
for 3 days. The resazurin reagent was then added to each well, incubated at 37 ◦C for 4 h, then
subsequently tested for fluorescence using a fluorometer at 560Ex nm and 590Em nm.
Ranges of drug concentrations (IRG = 1%, 0.1%, 0.01%, LEVO = 1%, 0.5%, 0.1%) were then tested
against the growth of cells (RAOSMCs).
2.6. Cell Proliferation Assay
A 5-bromo-2′-deoxyuridine (BrdU) assay was used to test the proliferation of cells (Sigma Aldrich,
Poole, UK). Cells were grown at a density of 3.6 × 104 cells/100 µL (in 96-well plates) for 3 days. Cell
proliferation was assessed based on 5-bromo-2′-deoxyuridine (BrdU) incorporation followed by ELISA
according to the manufacturer’s protocol. BrdU solutions were added to the well to achieve 1 nM
final concentration and incubated for 6 h. Cells were then washed, fixed and denatured at 37 ◦C for
30 min. Following successive washings with PBS, cellular BrdU uptake was detected by colorimetric
ELISA (450 nm) using anti-BrdU antibody. Data were normalized to the protein concentration of the
corresponding sample.
2.7. Statistical Analysis
All experiments were performed in triplicate with calculation of means and standard deviations.
Two-way analysis of variance (ANOVA) was used for multiple comparisons along with Tukey’s
multiple comparing tests, followed by a T-test to access statistical significance for paired comparisons.
Significance was acknowledged for p values lower than 0.05.
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3. Results
3.1. Cell Adhesion and Proliferation
The uniformity of fibres is shown through an SEM image in Figure 1. Initial 3-day studies of
RAOSMC growth against all PCL and PLA variations can be seen in Figures 2 and 3. The fluorescent
images in Figure 2 indicate there was no adhesion of cells on the PCL or PCL–collagen scaffolds,
and there appeared to be presence of a bacterial infection (bacteria not identified).
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RAOSMC adhesion was found to be minimal within both PCL–IRG and PCL–collagen–IRG
samples, with a cell density of approximately 1600 cells/cm2 and 500 cells/cm2. PCL–LEVO,
however, showed a cell adhesion density of approximately 14,000 cells/cm2 and 7500 cells/cm2
for PCL–collagen–LEVO.
Figure 3 indicates that there was no apparent cell adhesion of RAOSMCs against the PLA,
PLA–collagen and PLA–collagen–IRG scaffolds, with only a bacterial infection appearing in each case.
There was no cell adhesion measured for the PLA–IRG scaffold; however, no bacterial infection was
observed. Cell adhesion was observed for PLA–LEVO and PLA–collagen–LEVO scaffolds, with a cell
count of approximately 11,000 cells/cm2 and 2000 cells/cm2, respectively.
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A 14-day study was conducted on PCL–LEVO and PLA–LEVO combinations due to the highest
measurement of proliferative cells in the previous 3-day study. The results from this 14-day study can
be seen in Figures 4 and 5. PCL–LEVO showed a cell count across 3, 7 and 14 days of 6800, 140,000
and 98,000 cells/cm2. PCL–collagen–LEVO scaffold had a cell ount across 3, 7 and 14 days of 15 ,
180,000 and 130,000 cells/cm2.
Similar to the results of the 3-day study with PCL–LEVO/PCL–collagen–LEVO, greater
proliferation was measured against the PLA–LEVO and PLA–collagen–LEVO sc ffolds; therefore, the
14-day study tested against the scaffolds. PLA–LEVO scaffolds showed an average cell count of
7800, 128,000 and 119,000 cells/cm2 at 3, 7 an 14 days. PLA–collagen–LEVO scaffolds showed an
average cell count of 2,8 and 168,000 after 3 and 7 days, respectively, and at 14 days wa devoid of
cells (a bacterial infection was observed).
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An SEM image was also taken (Figure 6) that shows how the cells initially adhered within the
fibres after 3 days with subsequent proliferation after 14 days.
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3.2. Cell Viability
Data relating to the absorbance of resorufin from the resazurin assay can be seen in Figure 7.
Following the addition of 10% FCS to cells, metabolic activity increased by 24.82 ± 9.2% when
compared with quiesced cells in 0.1% FCS. The effect of 1% IRG had a detrimental effect on metabolic
activity, reducing it by 89.23 ± 0.48% below background activity (0.1% FCS). The effect of LEVO
was less harsh when compared with IRG, with an observed increase of 4.35 ± 7.89%. IRG reduced
activity by 91.37 ± 0.61% against 10% FCS. LEVO reduced metabolic activity against 10% FCS by
16.39 ± 5.41%.
M
i 7. Absorbance data with standard er or ba s (n = 3) for resazurin assay against BG (background)
10% fetal calf serum (FCS), 1% IRG and 0.5 LEVO concentrations. BG, IRG (1%), LEVO (0.5) vs. 10%
FCS * p < 0.05.
BrdU data is shown in Figure 8A,B. In comparison with the background, a high cell proliferation
was observed with the addition of 10% FCS. For the range of IRG concentrations, cell proliferation
increased for 0.01% and 0.1% concentrations and decreased in proliferation for 1% concentrations.
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LEVO concentrations generally showed a higher proliferation compared with the background, with cell
proliferation reducing as the concentration increased from 0.1% to 1%.Materials 2018, 11, x FOR PEER REVIEW  9 of 13 
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4. Discussion
Understanding the behaviour of smooth muscle cell (SMC) growth against scaffolds is important,
given the importance of SMCs within the development of tissue re-growth. Initial 3-day studies of
RAOSMCs against a number of PLA scaffold combinations proved insightful in determining which
scaffold/drug exhibited greatest efficacy in allowing cells to adhere. Bacterial infections were only
observed in the scaffolds that did not contain any antibacterial drug embedded within the polymeric
fibres. The source of the bacterial contamination was likely due to the tissue isolation procedure
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from the animals. Of course, any infection within the culture model is undesirable. However, in this
case what is noteworthy is contamination was prevented in all cases by the antibiotic combinations.
With respect to translational relevance, this is a potential verification of the potential value of this
antibiotic/polymer combination as a candidate for use in a surgical/clinical scenario of mesh implant
procedure where infection is highly possible. Typically, bacterial cells have been shown to invade
endothelial and smooth muscle cells in particular [23]. The addition of IRG across both PCL and
PLA samples proved detrimental to RAOSMCs adhesion. This may be largely due to the high
hydrophobicity of IRG in combination with two types of polymers that are generally hydrophobic in
nature—hydrophobicity typically hinders cell adhesion and proliferation [24].
There appeared to be a greater adherence of cells on LEVO-loaded scaffolds that did not contain
type I collagen; in the case of the PCL–LEVO and PCL–collagen–LEVO samples, both have the same
hydrophilic characteristics. However, the difference in cell adhesions cannot be attributed to this.
It is more likely the cells were interacting as a consequence of the variance in fibre diameters for
the two scaffolds, or the release of levofloxacin inhibiting bacteria may have affected cell adhesion.
Concerning the cell attachment against fibre diameter, it should be the case that scaffolds (in particular
PCL scaffolds) with smaller diameters (such as PCL–collagen–LEVO, with an average fibre diameter of
1.5 µm) would have better attachment of cells due to the increase in specific surface area [25]. However,
this was not the case. Thus, the decrease in cell attachment for the PCL–collagen–LEVO scaffold
may be due to factors that include drug release rate (there is a higher release percentage of drug
from the PCL–LEVO scaffolds compared with the PCL–collagen–LEVO scaffold (as demonstrated in
previous studies [22]), and an increase in bacterial resistance may help with cell adhesion), or simply
that the number of cells seeded onto the scaffolds were lower. PLA–LEVO and PLA–collagen–LEVO
scaffolds showed a lower cell adhesion count. This lower cell adhesion may have been attributed
to the high hydrophobicity (water contact angle ~108◦ for PLA–LEVO and ~132◦ water contact
angle for PLA–collagen–LEVO; these data sets were published in previous works [21]) and smaller
fibre diameter for the PLA–collagen–LEVO. Although a smaller fibre diameter could encourage cell
attachment, having fibres that range between 100 and 300 nm (of which there are some measured in the
PLA–collagen–LEVO scaffold) will not have a significant impact in the promotion of cell adhesion [17].
One explanation that the RAOSMCs are adhering and proliferating across the LEVO-loaded
scaffolds (for both PCL and PLA) may be due to the varying surface charges. It has been shown
in several studies that the most suitable conditions for cell adhesion and proliferation occur when
there is presence of negative ions associated with the surface treatment or drug of interest [26].
In particular, a carboxylic (–COOH) functional group is found predominately in the levofloxacin
compound; this functional group has a negative charge, with hydrophilic properties, and interacts
almost exclusively with fibronectin [27]. This interaction with fibronectin (which is typically found
within the extra cellular matrix of cultured cells) is important, because if the fibronectin protein is
adsorbed onto the scaffold surface, this allows for the anchoring of fibronectin to the cell [28]—in this
case allowing the RAOSMC to adhere to the scaffold surface.
Cell adhesion within the fibrous scaffolds can be seen in Figure 6. The structure of the cell
took shape according to the fibrous network it was surrounded by, extending in multiple directions
according to whatever direction a fibre was oriented. This was due to cells and nuclei becoming
elongated in order to adapt to the fibre structure, with the cell contracting in order to accommodate
within the fibrous network of the electrospun scaffolds [29]. A high confluence of cell proliferation
can be seen in Figure 6B, suggesting that initial success in cell adhesion allowed the smooth muscle to
proliferate over 14 days.
Examining the cell proliferation of RAOSMCs over 14 days was useful in demonstrating the
efficacy of the scaffolds against cell growth. We have demonstrated that cells had a higher level of
proliferation and confluence at 7 days (across PCL and PLA scaffolds), followed by a decrease in
proliferation at 14 days for most scaffolds (Figures 3 and 4). This decrease may be explained due
to the inhibition that is typically experienced when cell proliferation is at a high confluence [30].
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This particular cell line (RAOSMCs) also stops growing, and cells enter a senescence phase upon
reaching confluency [31]. Despite a reduced number of cell adhesions observed in scaffolds containing
collagen, this did not affect cell proliferation from 7 to 14 days. There is a possibility of the hydrophobic
bands (from collagen fibrils) being drawn to the surface of the fibres; therefore, it may be the case that
any cell–collagen interactions occurring may have been delayed due to hydrophobic forces [21].
We also observed that smooth muscle cells were growing in ‘lines’ on the PCL–collagen–LEVO
scaffold. This may be due to the fibre orientation of the sample, as fibres can be oriented in one
direction simply by stretching the scaffold in one direction. It may be the case that the samples were
stretched during the setup process (samples had to be removed from their aluminium backings, with
PCL–collagen–LEVO demonstrating high adhesion to the aluminium). However, this is an important
factor as cells will typically elongate and grow along a particular direction of aligned fibres [32].
Cell viability studies were useful in determining whether the levels of drug loaded into the
scaffolds had any potential toxic or inhibitory effects on the growth of RAOSMCs. It was clear from the
results that the concentration of IRG used (1%) was detrimental to cell growth and viability. IRG has an
EC50 value of approximately 0.0012 mg/mL [33]. Given that the 1% concentration used in the resazurin
assay was 0.57 mg/mL (475 times higher than the EC50 value), the reason for poor cell adhesion and
proliferation on IRG-loaded scaffolds was due to this high concentration. The BrdU assays were useful
in demonstrating the varying IRG concentrations directly against the proliferation of smooth muscle
cells—with 0.1% and 0.01% concentrations showing a more favourable response compared to the
1% IRG. It should also be noted that IRG has a mode of action where the drug can break through
membranes and demonstrate inhibitory effects, such as blocking of lipid biosynthesis [34], which may
be another plausible explanation as to why there was poor cell adhesion and proliferation.
We observed that the concentration of LEVO (0.5%) used in the initial resazurin study had no
measurable effect on cell metabolic activity when compared with controls. At this stage, it would
be safe to judge that the concentration of LEVO used was not detrimental to the growth and
proliferation of RAOSMCs. Further evidence of this was shown in the BrdU results, indicating
that an increase in concentration (to 1%) of LEVO decreased the proliferation of cells and that a
decrease in concentration (to 0.1%) permitted cell proliferation. This may be linked to the quoted EC50
value of 0.0074 mg/mL [35]—0.1% of LEVO used was 0.024 mg/mL, which is closer to the EC90 value.
5. Conclusions
Examining the cellular behaviour against polymeric scaffolds has proven extremely useful in
determining whether they have potential use for further development within the tissue-engineering
field. One of the main goals set out in this research was concerning how smooth muscle cells
proliferate/are compatible against the various scaffolds, and a number of important outcomes can
be taken from the results and discussion. Firstly, the use of irgasan within the polymeric scaffolds
proved to be detrimental to the adhesion and proliferation of cells. This was due to the concentration
of IRG used being far greater than the EC50 value quoted in various publications, which meant that it
was toxic to the cells growing in culture. Secondly, levofloxacin-loaded scaffolds showed the greatest
number of cell adhesions and subsequent proliferation over 14 days. This could be explained by the
hydrophilic nature of the drug (cells have a preference to grow in hydrophilic conditions); however,
a very high hydrophobicity of the PLA–collagen–LEVO scaffold was reported in our previous studies.
A more plausible explanation may be that the negatively carboxylic acid group found in LEVO was
attracting positively charged fibronectins, which in turn were attracting the cell to adhere to the
adsorbed proteins on the surface of the scaffold. Overall, the biological studies examined are useful as
preliminary data for potential further studies into more complex aspects of cell behaviour: for example,
understanding the behaviour of fibroblasts against electrospun scaffolds will help in understanding
potential scar formation at the site of insertion (e.g., by reducing scar tissue formation will help prevent
mesh adhesion) and in measuring inflammatory factors such as transforming growth factor beta 1
(TGF-β1) and interleukin 6 (IL-6).
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6. Study Perspective and Future Directions
This present study forms the first part of a planned program of work that may lead to the first
human clinical trials of a bio-compatible novel drug eluting polymer for mesh implant surgery. In this
study we have identified a number of important observations using in-vitro cell studies combined
with key drugs–polymer combinations. Our next stage will progress and develop this work to in-vivo
studies where the focus will be tissue integration and a systems biology assessment of our drug eluting
polymer mesh implants.
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